Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But ...

Google DeepMind's moonshot, Isomorphic Labs, is gearing up to launch its first ever human trial of AI-designed drugs. The ...

Alphabet’s Isomorphic Labs is preparing to begin human trials of a drug designed using AI, based on protein modelling ...

After years of development, Isomorphic Labs says its AI-created drugs are nearly ready for human trials. Isomorphic Labs, the ...

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 ...

Google DeepMind's Isomorphic Labs is preparing for human trials of AI-designed drugs, marking a significant advancement in ...

That work was honored with a Nobel Prize last year and spawned a drug-discovery spinout, Isomorphic Labs, and a boom of companies that hope AI will be able to propose new drugs.

That’s not nothing – but it’s also not the dramatic shift some headlines imply. It’s also important to distinguish between clinical trial results and how treatments perform in everyday care.

Neuron23 has partnered with Sano Genetics to streamline patient referrals and assist in the identification of people with PD who may be eligible to participate in the NEULARK clinical trial.

Novo and Hims’ April team-up turned the two firms from competitors into collaborators at just the right moment.